Antengene Corporation Limited (HKEX: 6996) has confirmed receipt of the USD 60 million upfront payment from UCB under their worldwide exclusive license agreement for ATG-201, a CD19/CD3 bispecific T-cell engager targeting B cell-related autoimmune diseases. The cash receipt, announced July 13, 2026, converts a deal signed in March 2026 into realized revenue — a meaningful inflection for Antengene as it transitions from a company historically known for in-licensing Western assets to one systematically monetizing its own proprietary TCE platform.
The original March 2026 agreement structured the Antengene UCB ATG-201 transaction as a full global out-license, with UCB acquiring worldwide exclusive rights to develop, manufacture, and commercialize the asset. Antengene retains no territorial commercialization rights. Under the terms, Antengene receives USD 80 million in upfront and near-term consideration — the USD 60 million upfront payment now confirmed received, plus USD 20 million in additional near-term milestone payments subject to undisclosed conditions. The company is also eligible for more than USD 1.1 billion in success-based development, regulatory, and sales milestones, along with tiered royalties on future net sales. Specific milestone breakdowns and royalty rates were not disclosed.
ATG-201 is described by Antengene as a CD19×CD3 bispecific TCE antibody built on its proprietary AnTenGager platform, which incorporates a "2+1" format — two CD19-binding arms and one CD3-binding arm — combined with steric hindrance masking technology designed to restrict T-cell activation to the presence of CD19-expressing target cells. The company presented preclinical data at ACR 2025 in October 2025, showing CD19-dependent CD3 binding, complete B-cell depletion in humanized mouse models, and a favorable safety profile in non-human primates at doses of 1–6 mg/kg with only mild, transient cytokine elevation. No Phase I human data existed at deal signing.
Since the license was executed, ATG-201's regulatory status has advanced. China's National Medical Products Administration approved the IND application for the Phase I ATTRACT study in June 2026. Antengene plans to conduct first-in-human studies in China and Australia before transferring further clinical development to UCB.